FORMULATION DEVELOPMENT AND IN-VITRO CHARACTERIZATION OF FAST DISSOLVING POLYMERIC FILMS OF OLANZAPINE FOR THE MANAGEMENT OF PANIC ATTACK OF SCHIZOPHRENIAAbstract
Schizophrenia is a severe and disabling disorder which needs immediate administration of a suitable drug. Olanzapine, a BCS class II atypical antipsychotics drug of thienobenzodiazepine class is frequently prescribed to treat schizophrenia. The aim of the present investigation was to formulate mouth dissolving films of Olanzapine to improve its solubility and patient compliance. An inclusion complex of Olanzapine with 2-hydroxypropyl-β-cyclodextrin at a molar ratio of 1:1 enhanced solubility of the drug. A patient compliant MDF using Pullalan as a film-forming polymer was developed using the design of the experiment, 32 factorial design. The independent variables selected for optimization of MDF containing inclusion complex of 2-hydroxypropyl-β-cyclodextrin and Olanzapine were polymer concentration (3-5%) and plasticizer concentration (25-35%). The optimized film demonstrated optimum tensile strength of 3.91(gm/cm2), the disintegration time of 15.45 seconds and fast dissolution of 99.3% in 6 minutes. All the films formulated using solvent casting method were smooth and elegant in appearance. Rapid release of Olanzapine from MDFs indicated its suitability as an oral delivery system in the management of panic attacks of depressive schizophrenia.
M. Momin *, S. Lalka, S. Mhatre and S. Mistry
Department of Pharmaceutics, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mithibai Campus, Mumbai, Maharashtra, India.
16 July 2018
24 October 2018
29 October 2018
01 April 2019